Antiretroviral therapy, or ART, can suppress HIV replication to levels at which standard clinical tests detect little or no virus in the blood. Suppression, however, does not normally eliminate infection. Viral genetic material can persist inside resting or slowly dividing immune cells, particularly CD4-positive T cells. Some of these cells contain proviruses that are transcriptionally silent, allowing them to evade immune recognition and the effects of drugs that target active replication. When ART is interrupted, a fraction of these proviruses can resume expression and generate new rounds of infection. The reservoir is therefore established early, maintained over time and difficult to remove once it has matured.

The study focuses on the period immediately after exposure, when the virus is expanding through susceptible tissues and disseminating between anatomical compartments. During this stage, infection is not simply a matter of increasing viral concentration in the bloodstream. Virus can enter lymphoid tissues, seed cellular niches and establish infected cells before treatment has fully controlled replication. The researchers used infant macaques to examine whether attacking the virus through several complementary mechanisms could reduce that early seeding process. Infant animals are particularly relevant to pediatric HIV research because their developing immune systems, patterns of immune-cell trafficking and clinical treatment circumstances differ from those of adults.

The first component of the intervention was ART, which targets viral enzymes or processes required for productive replication. By interrupting new infection cycles, ART rapidly reduces the amount of circulating virus and limits the generation of additional infected cells. Its activity is strongest against replication that is actively taking place, but it does not directly remove every cell that already contains integrated viral DNA. This distinction explains why ART is indispensable for controlling HIV yet insufficient by itself to eradicate the infection. In the experimental strategy, ART provided the foundation for suppression while the other components were intended to improve immune control and prevent the virus from reaching additional target cells.

Broadly neutralizing antibodies, often called bNAbs, contributed a second layer of protection. Unlike antibodies that recognize only a narrow viral variant, bNAbs bind conserved structures on the HIV envelope protein, the molecular machinery the virus uses to attach to and enter host cells. By occupying vulnerable regions of the envelope, these antibodies can prevent entry into new cells. They may also label infected cells or virus particles for clearance through Fc-mediated immune mechanisms, although the effectiveness of those functions depends on antibody properties, viral sensitivity and the state of the host immune system. The use of bNAbs is especially valuable in an early-treatment setting because it may combine immediate antiviral activity with immune engagement.

The third component targeted CCR5, a chemokine receptor found on many of the CD4-positive cells that HIV uses as early entry points. Viruses that use CCR5, known as R5-tropic viruses, attach to CD4 and then engage CCR5 to complete entry into the cell. Blocking this receptor can make susceptible cells less accessible, potentially reducing the number of successful infection events while viral replication is being brought under control. CCR5 blockade does not remove proviruses that are already integrated, and it cannot necessarily prevent infection by viruses that use alternative coreceptors. Its value in the combination therefore lies in reducing opportunities for further spread during a narrow but biologically important window.

Together, the three interventions address different stages of the infection cycle. ART suppresses replication inside infected cells and prevents the production of new virus. bNAbs can neutralize extracellular virus before it enters target cells and may recruit immune effector cells against infected targets. CCR5 blockade changes the availability of a major cellular entry route. The study’s central result is that this combined pressure limited viral reservoir seeding more effectively than would be expected from relying on a single mechanism alone. The work supports the idea that the reservoir is not an instantaneous, fixed feature of infection, but a dynamic population whose size and composition can be influenced during the earliest phase of disease.

The infant macaque model also allows investigators to examine tissues that cannot be routinely sampled in human infants, including lymph nodes and other sites where infected cells may persist. Such analyses are important because a low level of virus in blood does not necessarily indicate that reservoir formation has been prevented elsewhere. Reservoir measurements can include the amount of viral DNA, the frequency of cells carrying inducible virus and the ability of virus to rebound after treatment withdrawal. These measurements do not always yield identical estimates: much of the viral DNA detected in cells may be defective, while some intact proviruses remain deeply silent. The significance of the study therefore lies not only in blood suppression, but in its assessment of how early combination therapy affects the underlying tissue reservoir.

The findings do not demonstrate that HIV infection can be cured, nor do they establish that the same regimen would be safe, practical or equally effective in human infants. Antibody dosing, drug penetration into tissues, viral resistance, the timing of treatment and the developing immune system could all influence outcomes. CCR5-directed drugs may be active only against particular viral populations, while bNAbs can lose potency if the virus carries envelope variants that escape recognition. Even when a reservoir is reduced, a small number of intact proviruses may be sufficient to cause rebound after therapy is stopped. Human studies would therefore need to determine whether early combination treatment produces durable benefits without adding unacceptable toxicity or complexity to pediatric care.

Nevertheless, the study strengthens a broader strategy for HIV remission: intervene before the reservoir is extensively distributed, suppress replication with ART, protect vulnerable cells from infection and recruit antibody-mediated defenses against the virus. The approach could be relevant to infants exposed to HIV around birth, for whom rapid diagnosis and immediate treatment are already critical. It also provides a framework for testing next-generation bNAbs, longer-acting antiretroviral formulations and therapies designed to alter viral entry or immune-cell susceptibility. By showing that reservoir establishment can be constrained through coordinated intervention in an infant model, the work shifts attention from treating a fully established reservoir to preventing its formation in the first place.

Subject of Research: Combination therapy to limit HIV viral reservoir seeding in an infant macaque model.

Article Title: Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV.

Article References: Sacha, J.B., Ordonez, T., Pandey, S. et al. Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV. Nature Microbiology (2026). https://doi.org/10.1038/s41564-026-02444-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41564-026-02444-x

Keywords: HIV, viral reservoir, broadly neutralizing antibodies, antiretroviral therapy, CCR5 blockade, infant macaque model, HIV prevention, early treatment, viral suppression, HIV remission

Despite the potent suppression of HIV granted by modern ART, the virus’s ability to rebound rapidly after treatment cessation remains a formidable barrier to cure strategies. The persistence of latent viral reservoirs, invisible to the immune system and impervious to existing drugs, continuously threatens viral rebound once ART is stopped. Innovations to provoke robust and durable immune responses that can control viral replication independently of continuous drug therapy are urgently needed. The reported investigation addresses this challenge head-on by combining three distinct yet complementary immunotherapeutic components designed to synergize and ultimately contain HIV without ART.

The study enrolled ten individuals with well-controlled HIV on suppressive ART and subjected them to a sequence of interventions designed to stimulate both humoral and cellular immunity against the virus. The first key element was a novel therapeutic vaccine targeting conserved elements of the HIV Gag protein. This vaccine utilized a DNA prime enhanced with interleukin-12 (IL-12) followed by a modified vaccinia Ankara (MVA) boost. The rationale was to invoke a precise and potent CD8+ T cell response against viral epitopes that are functionally indispensable and less prone to mutation, thereby fostering effective cytotoxic T lymphocyte (CTL)-mediated control.

Following vaccination, participants received passive infusions of two broadly neutralizing antibodies (bNAbs): 10-1074 and VRC07-523LS. These bNAbs have been extensively characterized for their ability to neutralize diverse HIV strains by targeting conserved regions on the viral envelope glycoprotein, thereby preventing viral entry into host cells. Concurrently, the toll-like receptor 9 (TLR9) agonist lefitolimod was administered with the intent to activate innate immunity and potentially reverse viral latency, exposing infected cells to immune clearance.

This intricate immunotherapy regimen was administered during ongoing ART to prime and enhance the host immune responses in a controlled viral environment. After a period of immune modulation, ART was interrupted to assess whether the induced immunity could maintain control of viral rebound. To reinforce antibody-mediated activity, bNAbs were readministered at the moment of ART withdrawal, creating a frontline defense against early viral replication.

The outcomes were compelling. Remarkably, seven of the ten participants exhibited sustained viral control following ART interruption, maintaining low plasma viral loads independent of measurable bNAb concentrations. This indicates that the immune system, primed by vaccination and modulated by innate stimulants, was capable of exerting potent viral suppression without continuous pharmacologic intervention. In-depth immunologic analyses revealed that participants who achieved viral control had robust expansions of activated CD8+ T cells early after viral rebound, implicating these cells as critical effectors in controlling viral replication.

The study sheds light on the dynamic interplay between adaptive cellular immunity and antibody-mediated mechanisms during viral rebound. It also highlights a crucial role for innate immune stimulation in potentially enhancing antigen presentation and CTL activation. The ability of activated CD8+ T cells to correlate with lower median viral loads after peak viremia suggests a vital mechanistic underpinning for the observed post-treatment control — the immune system’s capacity to quickly and effectively respond to emerging virus.

This combination immunotherapy approach marks a significant advance over previous monotherapy or dual therapy attempts, which often failed to elicit durable control post-ART cessation. Therapeutic HIV vaccines alone have struggled to overcome immune exhaustion and viral diversity, while bNAbs face pharmacokinetic challenges and viral escape mutations. The elegant integration of vaccination, antibody therapy, and innate immune stimulation in a timed sequence appears to induce a more comprehensive immunologic milieu conducive to sustained control.

Importantly, the study also underscores the complexity of achieving ART-free remission in humans. Although seven participants maintained control, three did not, underscoring the need for continued optimization and personalization of immunotherapeutic protocols. Unraveling the immunogenetic or virologic determinants that differentiate responders from non-responders could pave the way for more tailored interventions in the future.

Beyond the immediate clinical implications for HIV cure research, these findings provide invaluable insights into the design of immunotherapies against persistent viral infections. The strategy of combining antigen-specific vaccination with passive immunization and innate immune agonists could be applicable to other challenging diseases requiring durable immune control.

While these preliminary results are highly encouraging, larger and longer-term clinical trials are necessary to confirm the durability and safety of such combination immunotherapies. Future iterations might explore the inclusion of additional latency-reversing agents, new-generation bNAbs with extended half-lives, or adjunct immune checkpoint blockade to further amplify T cell efficacy and overcome residual viral reservoirs.

Advancements in immunomonitoring techniques will be pivotal in dissecting the nuanced mechanisms driving viral control and immune resilience. Single-cell analyses, multi-parameter flow cytometry, and T cell receptor sequencing could reveal the breadth and functionality of vaccine-induced T cell clones, inform on the quality of bNAb-mediated neutralization, and chart the dynamics of innate immune activation post-intervention.

The promise this study offers is tantalizing — a future where people living with HIV might achieve sustained remission off ART, significantly improving quality of life and reducing the burden of lifelong medication adherence and drug toxicity. Although eradication of latent reservoirs remains a distant goal, effective immunologic control could transform HIV into a manageable chronic condition requiring only intermittent treatment boosts rather than daily drugs.

In conclusion, this pioneering combination immunotherapy regimen, through a coordinated orchestration of therapeutic vaccination, broadly neutralizing antibodies, and innate immunity activation, demonstrates for the first time in humans that sustained control of HIV post-ART is achievable. The correlation between early post-rebound CD8+ T cell activation and viral suppression offers an important biomarker and mechanistic insight into post-treatment control. These findings invigorate the HIV cure research community by validating the promise of integrated immunotherapeutic strategies and chart the course for future innovations aimed at attaining durable ART-free remission in people living with HIV.

Subject of Research:
HIV-1 infection and immunotherapeutic strategies aimed at inducing sustained ART-free control.

Article Title:
Correlates of HIV-1 control after combination immunotherapy.

Article References:

Peluso, M.J., Sandel, D.A., Deitchman, A.N. et al. Correlates of HIV-1 control after combination immunotherapy. Nature (2025). https://doi.org/10.1038/s41586-025-09929-5

Image Credits:
AI Generated